TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growthSander Palit, Michiel S. van der Heijden|eLife|2019Cited by 38
A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancerSander Palit, Michiel S. van der Heijden|Scientific Reports|2021Cited by 17
Decoding androgen receptor inhibitor resistance in prostate cancerSander Palit|Unknown|2022Cited by 0